Key result
IGFBP6 knockout in cardiac fibroblasts markedly attenuates post-MI fibrotic remodeling and ventricular dysfunction.
Fibroblast-derived IGFBP6 drives cardiac fibrosis via the EGR1-MFAP4 axis, presenting a potential novel therapeutic target for cardiac remodeling disorders.
Answers are grounded in this paper and cite their sources.
Does not support clinical targeting yet; leaves open validation of this axis in human cardiac remodeling trials.
Our study identifies fibroblast-derived IGFBP6 as a novel regulator of cardiac fibrosis through the EGR1-MFAP4 signaling axis, driving myofibroblasts differentiation and adverse remodeling. Targeting this pathway may offer therapeutic potential for cardiac remodeling disorders.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2025) studied Cardiac fibrosis and myocardial infarction (n=56). Cardiac fibroblast and myofibroblast-specific IGFBP6 knockout vs. IGFBP6 f/f (wild-type) mice was evaluated on Cardiac fibrosis, ventricular dysfunction, and infarct size. Conditional knockout of IGFBP6 in cardiac fibroblasts and myofibroblasts markedly attenuated post-myocardial infarction fibrotic remodeling, ventricular dysfunction, and isoproterenol-induced cardiac hypertrophy.
Synapse has enriched 10 related papers. Consider them for comparative context: